1CHESON B D,BENNETT J M,KOPECKY K J,et al.Revised recommendations of the International Working Group for Diagnosis,Standardization of Response Criteria,Treatment Outcomes,and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia[J].J Clin Oncol,2003,21(24):4642-4649.
2STRESEMANN C,BRUECKNER B,MUSCH T,et al.Functional diversity of DNA methyltransferase inhibitors in human cancer cell lins[J].Cancer Res,2006,66 (5):2794-2800.
3WlDSCHWENDTER A,M(U)LLER H M,FIEGL H,et al.DNA methylation in serum and tumors of cervical cancer patients[J].Clin Cancer Res,2004,10 (2):565-571.
4MURAl M,TOYOTA M,SATOH A,et al.Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours[J].Br J Cancer,2005,92 (6):1165-1172.
5HASEGAWA D,MANABE A,KUBOTA T,et al.Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia[J].Br J Haematol,2005,128 (6):805-81 2.
6JIANG Y,DUNBAR A,GONDEK L P,et al.Aberrant DNA methylation is a dominant mechanism in MDS progression to AML[J].Blood,2009,113 (6):1315-1325.
7Sl J,BOUMBER Y A,SHU J,et al.Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation[J].Cancer Res,2010,70 (17):6968-6977.
8ISSA J P,GARCIA-MANERO G,GILES F J,et al.Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza2'-deoxycytidine (decitabine) in hematopoietic malignancies[J].Blood,2004,103 (5):1635-1640.
9BLUM W,KLISOVIC R B,HACKANSON B,et al.Phase Ⅰ study of decitabine alone or in combination with valproic acid in acute myeloid leukemia[J].J Clin Oncol,2007,25 (25):3884-3891.
10GARCIA-MANERO G,KANTARJIAN H M,SANCHEZGONZALEZ B,et al.Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia[J].Blood,2006,108 (10):3271-3279.
